Patient-Reported Outcomes in First-Line Antiretroviral Therapy: Results from NEAT001/ANRS143 Trial Comparing Darunavir/Ritonavir in Combination with Tenofovir/Emtricitabine or Raltegravir

    loading  Checking for direct PDF access through Ovid



There are few data comparing patient reported outcomes (PROs) in randomized trials of initial antiretroviral therapy (ART). We present results from a substudy of the NEAT001/ANRS143 trial.


The randomized trial compared first-line DRV/r 800/100mg once daily plus RAL 400mg twice daily and DRV/r plus TDF/FTC 245/200mg once daily. Changes in PROs were assessed with 3 questionnaires: EuroQoL 5 domains (EQ-5D), Centre for Epidemiologic Studies Depression scale (CES-D), and HIV Treatment Satisfaction (HIVTSQ). Major Depressive Disorder (MDD) was defined as CES-d≥16. General estimating equations were used to model change over 96 weeks in PROs from baseline.


Of the 805 participants, 797(99%) contributed to the substudy. Baseline PROs data were similar for the two randomized groups. Health status improved over time with a mean increase in EQ-5D visual analogue scale of 8.0 by W96 (95%CI 6.5-9.4; p<0.001), and no statistically significant differences between groups (difference of 0.3 on VAS score (95%CI -1.7, 2.3); p=0.7, global p-value ≥0.05 for all domains over follow-up). There was no significant difference between groups on CES-D (difference of -0.1 (95%CI -1.3, 1.1); p=0.9), or MDD during follow-up, adjusted for baseline MDD (OR=0.98, 95%CI 0.82-1.18; p=0.9). RAL+DRV/r group had lower level of convenience (p=0.03) and fitted less well into patients’ lifestyle (p=0.007) than the TDF/FTC+DRV/r regimen, and was associated with lower treatment satisfaction (median score: 53 RAL+DRV/r vs 55 TDF/FTC+DRV/r (p=0.001).


PROs improved after starting ART, with no statistically significant difference between groups. The lower satisfaction with RAL+DRV/r may be explained by twice-daily administration.

Related Topics

    loading  Loading Related Articles